|
Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC
|
NCI
|
The National Cancer Institute (NCI) has collaborated with Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and other organizations to provide supplemental funding for the Medical Expenditure Panel Survey (MEPS) to improve the quality of data for estimating the cancer survivorship burden in the United States. Using responses to the National Health Interview Survey (NHIS) question about ever receiving a cancer diagnoses, households with cancer survivors were oversampled for selection in this MEPS supplement. The increased sample of cancer survivors will improve national estimates of the burden of cancer.
|
|
Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval.
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure.
|
|
Meta-Analysis Interagency Group (MATIG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS, NHLBI
|
The Meta-Analytical Interagency Group is an academic research collaboration between NHLBI, FDA and 2 other NIH institutions. This research collaboration is built among physician scientists, clinical trialists and data scientists from those agencies. MATIG's goal is to use data mining and machine learning tools and techniques for secondary analyses of clinical trials in order to maximize the use of data generated through clinical studies and highlight their public health value.
Other goals are to use publicly available patient-level data in BioLINCC for secondary- and meta-analyses to:
1) Assess hard outcomes in atherosclerotic and cardiometabolic disorders like diabetes, coronary artery disease and heart failure.
2) Determine gender, racial, and age group differences in efficacy, outcome, and utility of the interventions tested in the trials.
3) Promote the value of combining patient-level clinical trial data in meta-analysis.
4) Establish access to other publicly available datasets like EHR/EMR.
5) Foster hypothesis generation by novel analyses through a multidisciplinary collaboration.
6) Provide mentorship and training for students, scientists, and clinicians in today’s data science.
|
|
Microphysiological Systems for COVID Research (MPSCoRe): a joint working group to support global COVID-19 tissue chip activities
|
Resource Development
|
FDA
|
NIAID, NIEHS, NCATS
|
MPSCore connects researchers, methods developers, therapeutic/vaccine manufacturers, and regulators to maximize the scientific and public health usefulness of tissue-chips in understanding and treating COVID-19, as well as other diseases with epidemic potential.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC
|
The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the US Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
|
|
Mind Your Risks
|
Public Education Campaign
|
CDC, CMS
|
NINDS
|
The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia.
|
|
Models of Infectious Disease Agent Study (MIDAS)
|
Research Initiative
|
CDC
|
NIGMS, FIC, NIAID
|
Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems, and response strategies. The models will be useful to public health workers and researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid in our understanding of the disease and its spread.
|
|
Monthly Zika Vaccine Development Meeting
|
Resource Development
|
BARDA, FDA
|
NIAID
|
This working group is collaborating on development of assays and animal models for zika vaccines. Collaboration includes exchange of study data, study reports, and regulatory strategy for assay and model development and development of a regulatory package to support licensure of products through alternative pathways.
|
|
Multinational Influenza Seasonal Mortality Study (MISMS) Research
|
Research Initiative
|
FDA, OS
|
FIC, NHLBI, NIAID, NLM
|
The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses, on natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications.
|